

- Drug-induced illness, cutaneous (*Cont.*):
 genetic considerations in, 378
 global considerations in, 378
 hair disorders, 379–380
 hyperpigmentation, 360t, 361
 hypersensitivity reactions, 384t, 909t
 hypersensitivity syndrome. *See* Drug-induced hypersensitivity syndrome (DIHS)
 immediate, 377
 immune complex–dependent, 377
 incidence of, 377
 irritant/contact dermatitis, 381
 maculopapular eruptions, 380–381
 management of, 383–384
 nail disorders, 380
 overlap hypersensitivity syndromes, 383
 pathogenesis of, 377–378
 photosensitivity eruptions, 379, 379f, 389–390, 389t
 pigmentation changes, 379
 pruritus, 381
 pustular eruptions, 382. *See also* Acute generalized eruptive/exanthematous pustulosis (AGEP)
 reporting of, 385
 severe. *See* Stevens-Johnson syndrome; Toxic epidermal necrolysis
 “treating through” an eruption, 384
 urticaria/angioedema, 381
 vasculitis, 382, 2193
 vesicles/bullae, 361
 fatigue, 152
 fever of unknown origin, 138, 139
 liver injury. *See* Liver disease/failure, drug-induced
 lupus-like disease, 2134
 movement disorders, 2624
 musculoskeletal conditions, 2218t
 primary immunodeficiencies, 375e-2
 vasculitis, 2218t
- Drug-Induced Liver Injury Network (DILIN), 2025
- Drug interactions, 36, 41
 in elderly, 77–78
 with herbal/dietary supplements, 14e-4, 14e-4t
 in HIV infection, 798
 not mediated by changes in drug disposition, 43
 pharmacokinetic, 41–43, 42t
- Drug reaction with eosinophilia and systemic symptoms (DRESS). *See* Drug-induced hypersensitivity syndrome (DIHS)
- Drug-receptor interaction, 36
- Drug-target interactions, 40–41
- Drug-target network analysis, 87e-3
- Drusen
 vs. hard exudates, 40e-3
 in macular degeneration, 205, 205f
 optic disc, 203–204, 203f
- Dry beriberi, 96e-3, 2690
- Dry eye. *See* Keratoconjunctivitis sicca
- Dry mouth. *See* Xerostomia
- “Dry tap,” in bone marrow aspiration, 135e-1, 135e-2t
- DSDs. *See* Disorders of sex development (DSDs)
- DSGI/2* gene mutations, 2483
- DSHEA (Dietary Supplements Health and Education Act), 14e-3
- DTaP. *See* Diphtheria-tetanus-pertussis vaccine (DTaP)
- DTIC. *See* Dacarbazine (DTIC)
- DTPA, for internal radionuclide contamination, 263e-6t, 263e-7
- Dual-energy x-ray absorptiometry (DEXA), 2067, 2472, 2493
- Dual-process theory, 18
- Dual-task walking, 76, 162
- Dubin-Johnson syndrome, 282, 2003–2004, 2003t
- Duchenne’s muscular dystrophy, 462e-5
 clinical features of, 462e-5–6, 462e-5t
 diagnosis of, 462e-6
 early interventions for, 450t
 genetic considerations in, 436, 462e-5t, 462e-6
 genetic testing for, 450t
 incidence of, 462e-5
 pathogenesis of, 462e-6, 462e-8, 462e-8f
 treatment of, 462e-8
- Duck fever, 1681t
- Ductal carcinoma in situ, 531
- Duct of Luschka, bile leak from, 1885f
- Duffy-binding protein, 145e-3
- Duffy blood group system, 138e-1t, 138e-2
- Dugbe virus, 1308t
- Duke criteria, for infective endocarditis, 819, 819t
- Dulaglutide, 2414t
- Duloxetine
 adverse effects of, 2682t, 2710t
 for depression, 2710t
 for fibromyalgia, 2240, 2240t
 for neuropathic pain, 94–95, 2427, 2682t
 for osteoarthritis, 2232
 for pain, 91t, 94
- Dumping syndrome, 1926
- Duodenal neuroendocrine tumors, 563. *See also* Gastrointestinal neuroendocrine tumors (GI-NETs)
- Duodenal ulcers
 clinical features of, 1918
 complications of, 1918
 diagnosis of, 1881, 1881f, 1889f, 1918–1919, 1919f
 differential diagnosis of, 1918
 epidemiology of, 1914
 gastroduodenal mucosal defense and, 1912–1913, 1912–1914
H. pylori and. *See Helicobacter pylori* infection
 NSAID-induced, 1923–1924, 1923t
 pathology of, 1914
 pathophysiology of, 1915
 recurrence of, 1926
 treatment of, 346e-1v, 1890, 1924–1927, 1925f.
See also Peptic ulcer disease, treatment of
- Duodenitis, 277
- DUOX, 2285
- DUOXA, 2285
- Duplication, chromosome, 83e-1, 83e-6
- Duplication cyst, 277
- Dura, vascular malformations of, 2586, 2657, 2658f
- Durable power of attorney for health care, 59
- Dural sinus thrombosis, 2572
- Dura matter grafts, Creutzfeldt-Jakob disease after, 453e-4
- Duroziez’s sign, 411
- Dutasteride, 7e-4, 478, 580
- Duvenhage virus, 1304
- DUX4* gene, 462e-2f
- DVT. *See* Deep vein thrombosis (DVT)
- Dwarf tapeworm (*Hymenolepis nana*), 245e-2t, 246e-11, 765t, 1434
- Dynamic visual acuity, 149
- Dysbetalipoproteinemia, familial, 2440t, 2443
- Dysbiosis, 86e-1t
- Dyschondroplasia (Ollier’s disease), 426e-7, 594
- Dyschromic macules, 207e-3
- Dysembryoplastic neuroepithelial tumors, 603
- Dysentery
 in amebiasis. *See* Amebiasis
 etiology of, 266, 853
 in *Shigella* infections. *See Shigella* spp. infections
 treatment of, 268, 857
V. parahaemolyticus, 1065
- Dysesthesia, 158. *See also* Sensation, abnormalities of
- Dysferlin, 462e-8, 462e-8f
- Dysfibrinogenemia, 736, 739
- Dysfunctional uterine bleeding, 335
- Dysgerminoma
 brain, 2264
 ovary, 594–595
- Dysgeusia. *See* Taste disorders
- Dysgraphia, 179
- Dyshematopoietic syndrome, 729
- Dyshidrotic eczema. *See* Eczema, dyshidrotic
- Dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome)
 clinical features of, 102e-3, 359–360, 360t, 664
 genetic considerations in, 375e-1, 664, 2109
 pathogenesis of, 102e-3
- Dyskerin, 664
- Dyskinesia(s)
 diphasic, levodopa-related, 2614
 exercise-induced, 2624
 paroxysmal, 2624–2625
 pathophysiology of, 2613f
 tardive, 163, 261, 2624, 2722
- Dyslipedemias. *See* Lipoprotein disorders
- Dysmenorrhea, 338–339
- Dyspareunia, 330
- Dyspepsia. *See also* Indigestion
 clinical features of, 258, 1894
 endoscopy in, 1894
 functional (essential), 261, 1040, 1918
 new-onset, approach to, 1924, 1924f
 nonulcer, 1894, 1895
- Dysphagia, 254
 approach to the patient, 256–257, 256f
 in cranial nerve disorders, 2649
 diagnosis of, 257, 1895–1896, 1896f, 1897f
 esophageal, 256, 1901
 in esophageal cancer, 262, 533
 in gastric cancer, 534
 in GERD, 1907
 history in, 256–257
 involuntary weight loss and, 275
 in myasthenia gravis, 2701
 nutritional support in, 98e-3
 oropharyngeal, 256
 pathophysiology of, 255–256
 physical examination in, 257
 propulsive (motor), 255–256
 radiation therapy-related, 505
 with solids vs. liquids, 256
 structural, 255
 in terminally ill patient, 69t
 transfer, 1895
 treatment of, 258
- Dysphonia, 2649
- Dysplasia(s)
 of bone. *See* Bone disease
 fibromuscular, 1617, 1627, 1645, 2567
 pituitary, 2255–2256
 skeletal. *See* Chondrodysplasia(s)
- Dysplastic nevus, 76e-7f, 493–494, 493f
- Dyspnea, 47e-1
 anxiety and, 47e-1
 in aortic stenosis, 1530
 approach to the patient, 47e-3, 47e-4f
 assessment of, 47e-1–2, 62, 1661
 in cardiovascular disease, 47e-1t, 47e-2, 47e-4, 1439, 1503–1504
 in COPD, 1704
 in cor pulmonale, 1506
 definition of, 47e-1
 differential diagnosis of, 47e-2, 47e-4
 efferent-afferent mismatch in, 47e-1f
 exertional, 47e-4
 history in, 47e-3
 imaging in, 47e-4
 intensity and quality of, 47e-1–2, 47e-1t
 laboratory studies in, 47e-4
 nocturnal, 47e-3
 in orthostatic hypotension, 146
 pathophysiology of, 47e-1, 47e-1f
 physical examination in, 47e-3–4
 in pulmonary hypertension, 1655
 in respiratory acidosis, 322
 in respiratory disease, 47e-2, 47e-2t, 47e-4, 1661
 in terminally ill patient, 62, 62t
 treatment of, 47e-4, 62, 62t
- Dysreflexia, autonomic, 2641–2642
- Dysthymic disorder, 2715
- Dystonia, 2620
 clinical features of, 163, 2619t, 2620
 drug-induced, 65, 2624
 focal, 2620